113 related articles for article (PubMed ID: 10553082)
1. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor.
Graf MR; Jadus MR; Hiserodt JC; Wepsic HT; Granger GA
J Immunol; 1999 Nov; 163(10):5544-51. PubMed ID: 10553082
[TBL] [Abstract][Full Text] [Related]
2. Membrane macrophage colony-stimulating factor on MADB106 breast cancer cells does not activate cytotoxic macrophages but immunizes rats against breast cancer.
Williams CC; Trinh H; Tran TV; Dan Q; Sanchez R; Delgado C; Chen Y; Sippel B; Jeffes EW; Wepsic HT; Jadus MR
Mol Ther; 2001 Feb; 3(2):216-24. PubMed ID: 11237678
[TBL] [Abstract][Full Text] [Related]
3. Non-immunogenic murine hepatocellular carcinoma Hepa1-6 cells expressing the membrane form of macrophage colony stimulating factor are rejected in vivo and lead to CD8+ T-cell immunity against the parental tumor.
Dan Q; Sanchez R; Delgado C; Wepsic HT; Morgan K; Chen Y; Jeffes EW; Lowell CA; Morgan TR; Jadus MR
Mol Ther; 2001 Nov; 4(5):427-37. PubMed ID: 11708879
[TBL] [Abstract][Full Text] [Related]
4. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
5. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
6. T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas.
Sanchez R; Williams C; Daza JL; Dan Q; Xu Q; Chen Y; Delgado C; Arpajirakul N; Jeffes EW; Kim RC; Douglass T; Al Atar U; Terry Wepsic H; Jadus MR
Cell Immunol; 2002 Jan; 215(1):1-11. PubMed ID: 12142031
[TBL] [Abstract][Full Text] [Related]
7. Macrophages kill T9 glioma tumor cells bearing the membrane isoform of macrophage colony stimulating factor through a phagocytosis-dependent pathway.
Jadus MR; Williams CC; Avina MD; Ly M; Kim S; Liu Y; Narasaki R; Lowell CA; Wepsic HT
J Immunol; 1998 Jan; 160(1):361-8. PubMed ID: 9551992
[TBL] [Abstract][Full Text] [Related]
8. Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression of three different heat shock proteins.
Jadus MR; Chen Y; Boldaji MT; Delgado C; Sanchez R; Douglass T; Al-Atar U; Schulz W; Lloyd C; Wepsic HT
Cancer Gene Ther; 2003 May; 10(5):411-20. PubMed ID: 12719711
[TBL] [Abstract][Full Text] [Related]
9. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor.
Ge L; Zhang JG; Samathanam CA; Delgado C; Tarbiyat-Boldaji M; Dan Q; Hoa N; Nguyen TV; Alipanah R; Pham JT; Sanchez R; Wepsic HT; Morgan TR; Jadus MR
Cell Immunol; 2009; 259(2):117-27. PubMed ID: 19615673
[TBL] [Abstract][Full Text] [Related]
11. Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a "paraptosis"-induced pathway that promotes systemic immunity against intracranial T9 gliomas.
Chen Y; Douglass T; Jeffes EW; Xu Q; Williams CC; Arpajirakul N; Delgado C; Kleinman M; Sanchez R; Dan Q; Kim RC; Wepsic HT; Jadus MR
Blood; 2002 Aug; 100(4):1373-80. PubMed ID: 12149220
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 transduction of a rat T9 glioma clone results in attenuated tumorigenicity and induces glioma immunity in Fischer F344 rats.
Graf MR; Merchant RE
J Neurooncol; 1999; 45(3):209-18. PubMed ID: 10845391
[TBL] [Abstract][Full Text] [Related]
13. Generation of human innate immune responses towards membrane macrophage colony stimulating factor (mM-CSF) expressing U251 glioma cells within immunodeficient (NIH-nu/beige/xid) mice.
Delgado C; Hoa N; Callahan LL; Schiltz PM; Jahroudi RA; Zhang JG; Wepsic HT; Jadus MR
Cytokine; 2007 Jun; 38(3):165-76. PubMed ID: 17689258
[TBL] [Abstract][Full Text] [Related]
14. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.
Okada H; Villa L; Attanucci J; Erff M; Fellows WK; Lotze MT; Pollack IF; Chambers WH
Gene Ther; 2001 Aug; 8(15):1157-66. PubMed ID: 11509946
[TBL] [Abstract][Full Text] [Related]
15. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH
Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of antitumor immunity using genetically M-CSF-expressing L1210 cells.
Kimura F; Douzono M; Ohta J; Morita T; Ikeda K; Nakamura Y; Sato K; Yamada M; Nagata N; Motoyoshi K
Exp Hematol; 1996 Feb; 24(2):360-3. PubMed ID: 8641366
[TBL] [Abstract][Full Text] [Related]
17. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity.
Graf MR; Prins RM; Merchant RE
J Immunol; 2001 Jan; 166(1):121-9. PubMed ID: 11123284
[TBL] [Abstract][Full Text] [Related]
18. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
[TBL] [Abstract][Full Text] [Related]
20. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
